Current Neuro-Oncology

Volume 26 Number 26
20 November 2024

Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 26, 20 November

Cozzens JW, Lokaitis BC, Delfino K, Hoeft A, Moore BE, Fifer AS, Amin DV, Espinosa JA, Jones BA, Acakpo-Satchivi L.
A Phase 2 Sensitivity and Selectivity Study of High-Dose 5-Aminolevulinic Acid in Adult Patients Undergoing Resection of a Newly Diagnosed or Recurrent Glioblastoma.
Oper Neurosurg (Hagerstown). 2024 Nov 11. doi: 10.1227/ons.0000000000001417. PMID: 39526779. Interventional study˰ ˍ

Colliva C, Rivi V, Sarti P, Cobelli I, Blom JMC.
Exploring Sex-Based Neuropsychological Outcomes in Pediatric Brain Cancer Survivors: A Pilot Study.
Diseases. 2024 Nov 11;12(11):289. doi: 10.3390/diseases12110289. PMID: 39589963. Observational study. ˍ

*El-Hajj VG, Ranganathan S, Hoang H, Ghaith AK, Bydon M, Elmi-Terander A.
The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis.
J Neurooncol. 2024 Nov 11. doi: 10.1007/s11060-024-04880-3. PMID: 39527384. Observational study. ˍ

Gdynia HJ, Schneiderat P, Gratzer A, Wiedhopf K, Gdynia N, Haase I.
Clinical features and rehabilitation outcome after surgical treatment of spinal meningioma.
Spinal Cord Ser Cases. 2024 Nov 11;10(1):75. doi: 10.1038/s41394-024-00688-5. PMID: 39528486. Observational study˰ ˍ

Kanamori M, Shibahara I, Shimoda Y, Akiyama Y, Beppu T, Ohba S, Enomoto T, Ono T, Mitobe Y, Hanihara M, Mineharu Y, Ishida J, Asano K, Yoshida Y, Natsumeda M, Nomura S, Abe T, Yonezawa H, Katakura R, Shibui S, Kuroiwa T, Suzuki H, Takei H, Matsushita H, Saito R, Arakawa Y, Sonoda Y, Hirose Y, Kumabe T, Yamaguchi T, Endo H, Tominaga T.
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection.
Int J Clin Oncol. 2024 Nov 11. doi: 10.1007/s10147-024-02650-9. PMID: 39527165. Interventional study. ˍ

*Puranik AD, Dev ID, Rangarajan V, Jain Y, Patra S, Purandare NC, Sahu A, Choudhary A, Bhattacharya K, Gupta T, Chatterjee A, Dasgupta A, Moiyadi A, Shetty P, Singh V, Sridhar E, Sahay A, Shah A, Menon N, Ghosh S, Choudhury S, Shah S, Agrawal A, Lakshminarayanan N, Kumar A, Gopalakrishna A.
FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study.
Neuroradiology. 2024 Nov 11. doi: 10.1007/s00234-024-03495-9. PMID: 39527264. Observational study. ˍ

*Wee CW, Lee JH, Lee HI, Kim J, Chang JH, Kang SG, Kim EH, Moon JH, Cho J, Park CK, Kim CY, Hwang K, Yoon HI, Kim IA.
To Use or Not to Use: Temozolomide in Elderly Patients with IDH Wild-type MGMT Promoter Unmethylated Glioblastoma Treated with Radiotherapy.
Cancer Res Treat. 2024 Nov 11. doi: 10.4143/crt.2024.945. PMID: 39529389. Observational study. ˍ

Johnstad C, Reinertsen I, Thurin E, Dunås T, Bouget D, Sagberg LM, Jakola AS, Solheim O.
The prognostic importance of glioblastoma size and shape.
Acta Neurochir (Wien). 2024 Nov 12;166(1):450. doi: 10.1007/s00701-024-06351-0. PMID: 39531176. Observational study. ˍ

*Lau ACK, Chan BLH, Yeung CSK, Li LF, Chan DTM, Lee MWY, Chan TKT, Ho JMK, Cheung KM, Tse TPK, Lau SSN, Chow JSW, Ko NMW, Loong HHF, El-Helali A, Poon WS, Woo PYM.
The impact of timing of temozolomide chemoradiotherapy for newly diagnosed glioblastoma on patient overall survival: A multicenter retrospective study.
Neurooncol Adv. 2024 Nov 12;6(1):vdae194. doi: 10.1093/noajnl/vdae194. PMID: 39659837. Observational study. ˍ

Berghaus N, Hielscher T, Savran D, Schrimpf D, Maas SLN, Preusser M, Weller M, Acker T, Herold-Mende C, Wick W, von Deimling A, Sahm F.
Meningiomas: Sex-Specific Differences and Prognostic Implications of a Chromosome X Loss.
Neuro Oncol. 2024 Nov 13:noae239. doi: 10.1093/neuonc/noae239. PMID: 39535060. Observational study; Laboratory investigation˰ ˍ

Bonaventure A, Simpson J, Kane E, Roman E.
Maternal illnesses during pregnancy and the risk of childhood cancer: A medical-record based analysis (UKCCS).
Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35166. PMID: 39535336. Observational study. ˍ

Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, Barsan V, Song KW, Kamens J, Baggott C, Kunicki M, Rietberg SP, Lim AS, Reschke A, Mavroukakis S, Egeler E, Moon J, Patel S, Chinnasamy H, Erickson C, Jacobs A, Duh AK, Tunuguntla R, Klysz DD, Fowler C, Green S, Beebe B, Carr C, Fujimoto M, Brown AK, Petersen AG, McIntyre C, Siddiqui A, Lepori-Bui N, Villar K, Pham K, Bove R, Musa E, Reynolds WD, Kuo A, Prabhu S, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Grant G, Prolo L, Ye X, Sahaf B, Davis KL, Feldman SA, Ramakrishna S, Mackall C.
Intravenous and intracranial GD2-CAR T cells for H3K27M⁺ diffuse midline gliomas.
Nature. 2024 Nov 13. doi: 10.1038/s41586-024-08171-9. PMID: 39537919. Interventional study. ˍ

Petitt JC, Murayi R, El-Abtah ME, Momin A, Halima A, Potter T, Ahorukomeye P, Jarmula J, Thapliyal M, Murphy ES, Chao ST, Suh JH, Recinos PF, Kshettry VR.
Outcomes of adjuvant radiation treatment following subtotal resection of world health organization grade II meningiomas.
J Neurooncol. 2024 Nov 13. doi: 10.1007/s11060-024-04878-x. PMID: 39538039. Observational study˰ ˍ

Hovman FR, Poulsen FR, Hansen S, Dahlrot RH.
The risk of venous thromboembolism in adult patients with diffuse glioma: a nationwide population-based study.
Acta Oncol. 2024 Nov 14;63:887-892. doi: 10.2340/1651-226X.2024.40137. PMID: 39543846. Observational study. ˍ

*Sharifian A, Kazemian A, Farzin M, Amirkhani N, Farazmand B, Naderi S, Khalilian A, Pourrashidi A, Amjad G, Kolahdouzan K, Abyaneh R, Jablonska PA, Ghalehtaki R.
Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.
Neurooncol Adv. 2024 Nov 14;6(1):vdae195. doi: 10.1093/noajnl/vdae195. PMID: 39664679. Interventional study. ˍ

Tini P, Cinelli E, Yavorska M, Donnini F, Marampon F, Pastina P, Rubino G, Chibbaro S, Cerase A, Mazzei MA, Di Giacomo AM, Minniti G.
Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol.
J Neurooncol. 2024 Nov 14. doi: 10.1007/s11060-024-04862-5. PMID: 39540980. Observational study˰ ˍ

Atsukawa N, Tatekawa H, Ueda D, Oura T, Matsushita S, Horiuchi D, Takita H, Mitsuyama Y, Baba R, Tsukamoto T, Shimono T, Miki Y.
Visualizing the association between the location and prognosis of isocitrate dehydrogenase wild-type glioblastoma: a voxel-wise Cox regression analysis with open-source datasets.
Neuroradiology. 2024 Nov 15. doi: 10.1007/s00234-024-03503-y. PMID: 39542911. Observational study˰ ˍ

Hallal SM, Sida LA, Tűzesi CÁ, Shivalingam B, Sim HW, Buckland ME, Satgunaseelan L, Alexander KL.
Size matters: Biomolecular compositions of small and large extracellular vesicles in the urine of glioblastoma patients.
J Extracell Biol. 2024 Nov 15;3(11):e70021. doi: 10.1002/jex2.70021. PMID: 39554867. Laboratory investigation. ˍ

Han X, Xiao K, Bai J, Li F, Cui B, Cheng Y, Liu H, Lu J.
Multimodal MRI and ¹H-MRS for Preoperative Stratification of High-Risk Molecular Subtype in Adult-Type Diffuse Gliomas.
Diagnostics (Basel). 2024 Nov 15;14(22):2569. doi: 10.3390/diagnostics14222569. PMID: 39594235. Observational study. ˍ

*Inoue H, Kuroda JI, Fujioka Y, Hata N, Mizoguchi M, Yoshii D, Sueyoshi H, Takeshima Y, Fujimoto K, Shinojima N, Sunami K, Mikami Y, Nakamura H, Mukasa A.
Drug-resistant BRAF V600E-mutant recurrent pleomorphic xanthoastrocytoma, CNS WHO Grade 3 successfully resolved with incidental discontinuation of combined BRAF and MEK inhibitor therapy.
Surg Neurol Int. 2024 Nov 15;15:417. doi: 10.25259/SNI_734_2024. PMID: 39640311. Case report. ˍ

Näslund O, Jakobsson S, Thurin E, Skoglund T, Pettersson-Segerlind J, Brynedal B, Jakola AS, Bartek J Jr.
Health-related quality of life in surgically treated asymptomatic meningioma patients: A population-based matched cohort study.
Neurooncol Pract. 2024 Nov 15;11(6):723-732. doi: 10.1093/nop/npae047. PMID: 39554792. Observational study. ˍ

Pinchuk A, Tonchev N, Dumitru CA, Neyazi B, Stein KP, Sandalcioglu IE, Rashidi A.
Risk of Postoperative Hemorrhage After Glioma Surgery in Patients with Preoperative Acetylsalicylic Acid.
Cancers (Basel). 2024 Nov 15;16(22):3845. doi: 10.3390/cancers16223845. PMID: 39594800. Observational study. ˍ

Bai X, Xing H, Feng M, Ma W, Wang S.
Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.
Cancer Manag Res. 2024 Nov 16;16:1617-1626. doi: 10.2147/CMAR.S481289. PMID: 39575164. Observational study. ˍ

Strauss JD, Gilbert MR, Mehta M, Li A, Ms RZ, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard MA, Pugh SL, Armstrong TS, Scheurer ME.
Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825.
Neuro Oncol. 2024 Nov 16:noae234. doi: 10.1093/neuonc/noae234. PMID: 39549280. Observational study˰ ˍ

Singer S, Schranz M, Hippler M, Kuchen R, Weiß Lucas C, Meixensberger J, Fehrenbach MK, Keric N, Mitsdoerffer M, Gempt J, Coburger J, Kessler AF, Wehinger J, Misch M, Onken J, Rapp M, Voß M, Nadji-Ohl M, Mehlitz M, Tatagiba M, Tabatabai G, Renovanz M.
Frequency and clinical associations of common mental disorders in adults with high-grade glioma-A multicenter study.
Cancer. 2024 Nov 17. doi: 10.1002/cncr.35653. PMID: 39550627. Observational study. ˍ

Asioli S, Gatto L, Vardy U, Agostinelli C, Di Nunno V, Righi S, Tosoni A, Ambrosi F, Bartolini S, Giannini C, Franceschi E.
Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study.
Cancers (Basel). 2024 Nov 18;16(22):3859. doi: 10.3390/cancers16223859. PMID: 39594814. Observational study. ˍ

*Elia A, Roux A, Trancart B, Moiraghi A, Seneca M, Dezamis E, Varlet P, Chretien F, Oppenheim C, Zanello M, Pallud J.
Watch-and-wait approach versus adjuvant treatment after radical awake resection in selected adult-type grade 3 gliomas, isocitrate dehydrogenase mutant: A case-matched cohort.
Neurooncol Adv. 2024 Nov 18;6(1):vdae189. doi: 10.1093/noajnl/vdae189. PMID: 39620200. Observational study. ˍ

Guo CC, Yang QY, Xi SY, Zhou J, Zhou ZH, Cao X, Liao YX, Li BX, Dai XR, Wong M, Li YJ, Yu XH, Chen ZP.
Phase I clinical study of a multi-kinase inhibitor TG02 capsule for the treatment of recurrent high-grade gliomas with failed temozolomide treatment in Chinese patients.
Chemotherapy. 2024 Nov 18:1-24. doi: 10.1159/000542365. PMID: 39557019. Interventional study˰ ˍ

Henriksen OM, Muhic A, Lundemann MJ, Larsson HBW, Lindberg U, Andersen TL, Hasselbalch B, Møller S, Marner L, Madsen K, Larsen VA, Poulsen HS, Hansen AE, Law I.
Added prognostic value of DCE blood volume imaging in patients with suspected recurrent or residual glioblastoma-A hybrid [¹⁸F]FET PET/MRI study.
Neurooncol Adv. 2024 Nov 18;6(1):vdae196. doi: 10.1093/noajnl/vdae196. PMID: 39664680. Observational study. ˍ

Jimson D Jimenez M, Mohiuddin M, Li D, Ruge JR.
Treatment of cerebral radiation necrosis using hyperbaric oxygen therapy in a child: illustrative case.
J Neurosurg Case Lessons. 2024 Nov 18;8(21):CASE24460. doi: 10.3171/CASE24460. PMID: 39556802. Case report. ˍ

Sørensen MD, Olsen RFS, Burton M, Kavan S, Petterson SA, Thomassen M, Kruse TA, Meyer M, Kristensen BW.
Microglia induce an interferon-stimulated gene expression profile in glioblastoma and increase glioblastoma resistance to temozolomide.
Neuropathol Appl Neurobiol. 2024 Nov 18;50(6):e13016. doi: 10.1111/nan.13016. PMID: 39558550. Laboratory investigation. ˍ

Vora S, Pafundi D, Voss M, Buras M, Ashman J, Bendok B, Breen W, Hu L, Kizilbash S, Laack N, Liu W, Mahajan A, Mrugala M, Porter A, Ruff M, Sio T, Uhm J, Yang M, Brinkmann D, Brown P.
Short-course hypofractionated proton beam therapy, incorporating ¹⁸F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.
Lancet Oncol. 2024 Nov 18:S1470-2045(24)00585-0. doi: 10.1016/S1470-2045(24)00585-0. PMID: 39571596. Interventional study˰ ˍ

Zhao D, Duan L, Juratli TA, Shen F, Zhou L, Cui S, Zhang H, Ren H, Cheng L, Wang H, Shi W, Li T, Li M.
Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas.
Ann Clin Transl Neurol. 2024 Nov 18. doi: 10.1002/acn3.52251. PMID: 39556508. Observational study. ˍ

Karajannis MA, Onar-Thomas A, Lin T, Baxter PA, Boué DR, Cole BL, Fuller C, Haque S, Jabado N, Lucas JT Jr, MacDonald SM, Matsushima C, Patel N, Pierson CR, Souweidane MM, Thomas DL, Walsh MF, Zaky W, Leary SES, Gajjar A, Fouladi M, Cohen KJ.
Phase 2 Trial of Veliparib, Local Irradiation and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma: A Children's Oncology Group Study.
Neuro Oncol. 2024 Nov 19:noae247. doi: 10.1093/neuonc/noae247. PMID: 39560182. Interventional study˰ ˍ

Krenzlin H, Jankovic D, Dauth A, Lange F, Wetzel M, Schmidt L, Janssen I, Richter C, Stockinger M, Schmidberger H, Brockmann MA, Sommer C, Meyer B, Keric N, Ringel F.
Multimodal treatment of glioblastoma with multiple lesions - a multi-center retrospective analysis.
J Neurooncol. 2024 Nov 19. doi: 10.1007/s11060-024-04810-3. PMID: 39560695. Observational study. ˍ

Tabatabai G, Platten M, Preusser M, Weller M, Wick W, van den Bent M.
Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lessons ignored?
Neuro Oncol. 2024 Nov 19:noae225. doi: 10.1093/neuonc/noae225. PMID: 39561243. Comment. ˍ
REFERS TO:
Latzer P, Zelba H, Battke F, Reinhardt A, Shao B, Bartsch O, Rabsteyn A, Harter J, Schulze M, Okech T, Golf A, Kyzirakos-Feger C, Kayser S, Pieper N, Feldhahn M, Wünsche J, Seitz C, Hadaschik D, Garbe C, Hauser TK, la Fougère C, Biskup D, Brooke D, Parker D, Martens UM, Illerhaus G, Blumenthal DT, Merrell R, Lorenzo LS, Hidvégi M, de Robles P, Kebir S, Li WW, Li VW, Williams M, Miller AM, Kesari S, Castro M, Desjardins A, Ashley DM, Friedman HS, Wen PY, Neil EC, Iwamoto FM, Sipos B, Geletneky K, Zender L, Glas M, Reardon DA, Biskup S.
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.
Nat Commun. 2024 Aug 11;15(1):6870. doi: 10.1038/s41467-024-51315-8. PMID: 39127809. Observational study. ˍ

Tang L, Chakravarti S, Li E, Mao Y, Ahmed AK, Mukherjee D.
Optimal treatment regimen for very elderly patients with atypical meningioma: an analysis of survival outcomes using the National Cancer Database (NCDB).
J Neurooncol. 2024 Nov 19. doi: 10.1007/s11060-024-04886-x. PMID: 39560694. Observational study˰ ˍ

Calim Gurbuz B, Soylemez Akkurt T, Kusku Cabuk F, Sencan F, Tugcu B, Ersen Danyeli A.
Olıgosarcoma: A Rare Case Report Wıth Dıstınct Features.
Int J Surg Pathol. 2024 Nov 20:10668969241291891. doi: 10.1177/10668969241291891. PMID: 39563510. Case report˰ ˍ

Hafez RFA, Fahmy OM, Hassan HT, Ganz JC.
Gamma Knife Radiosurgery for symptomatic eloquently deep-seated cystic pilocytic astrocytoma mural nodules: Retrospective case series of effective outcomes.
Acta Neurochir (Wien). 2024 Nov 20;166(1):466. doi: 10.1007/s00701-024-06366-7. PMID: 39565484. Observational study˰ ˍ

Shao Z, Yan H, Zhu M, Liu Z, Chen Z, Li W, Wang C, Zhang L, Zheng J.
The impact of the subventricular zone invasion types and MGMT methylation status on tumor recurrence and prognosis in glioblastoma.
Heliyon. 2024 Nov 20;10(23):e40558. doi: 10.1016/j.heliyon.2024.e40558. PMID: 39687126. Observational study. ˍ

Turco L, Della Monica R, Giordano P, Cuomo M, Biazzo M, Mateu B, Di Liello R, Daniele B, Normanno N, De Luca A, Rachiglio AM, Chiaramonte C, Giugliano FM, Chiariotti L, Catapano G, Coretti L, Lembo F.
Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion-positive glioblastoma.
Front Oncol. 2024 Nov 20;14:1458990. doi: 10.3389/fonc.2024.1458990. PMID: 39634265. Case report. ˍ